8YO3

structure of phage T4 topoisomerase II central domain

Summary for 8YO3

• Entry DOI: 10.2210/pdb8yo3/pdb
• EMDB information: 39434
• Descriptor: DNA topoisomerase medium subunit, phage T4 topoisomerase II gp39-gp60 subunit (2 entities in total)
• Functional Keywords: topoisomerase ii, isomerase
• Biological source: Escherichia phage T4; More
• Total number of polymer chains: 4
• Total formula weight: 256190.45

Authors

Chen, Y.T.,Xin, Y.H.,Xian, R.Q. (deposition date: 2024-03-12, release date: 2024-09-25, Last modification date: 2025-10-08)

Primary citation

Xin, Y.,Xian, R.,Yang, Y.,Cong, J.,Rao, Z.,Li, X.,Chen, Y.
Structural and functional insights into the T-even type bacteriophage topoisomerase II.
Nat Commun, 15:8719-8719, 2024

PubMed Abstract: T-even type bacteriophages are virulent phages commonly used as model organisms, playing a crucial role in understanding various biological processes. One such process involves the regulation of DNA topology during phage replication upon host infection, governed by type IIA DNA topoisomerases. In spite of various studies on prokaryotic and eukaryotic counterparts, viral topoisomerase II remains insufficiently understood, especially the unique domain composition of T4 phage. In this study, we determine the cryo-EM structures of topoisomerase II from T4 and T6 phages, including full-length structures of both apo and DNA-binding states which have never been determined before. Together with other conformational states, these structures provide an explicit blueprint of mechanisms of phage topoisomerase II. Particularly, the asymmetric dimeric interactions observed in cryo-EM structures of T6 phage topoisomerase II ATPase domain and central domain bound with DNA shed light on the asynchronous ATP usage and asynchronous cleavage of the G-segment DNA, respectively. The elucidation of phage topoisomerase II's structures and functions not only enhances our understanding of mechanisms and evolutionary parallels with prokaryotic and eukaryotic homologs but also highlights its potential as a model for developing type IIA topoisomerase inhibitors.

PubMed: 39379365
DOI: 10.1038/s41467-024-53037-3

Experimental method

ELECTRON MICROSCOPY (3.62 Å)